Clinical Trial Update: A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial of venglustat for autosomal dominant polycystic kidney disease was terminated; results were posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polycystic Kidney Disease Autosomal Dominant

Drugs mentioned

• Venglustat (venglustat)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Polycystic Kidney, Autosomal Dominant | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2022-11-09